HepatologyNews.net

Hepatology Xagena

Search results for "Interferon"

European Commission has approved Pegasys ( Peginterferon alfa-2a ) for the treatment of chronic hepatitis B. The approval is granted for both types of the disease, HBeAg-positive and HBeAg-negativ ...


More than half of 61 children and adolescents infected with chronic hepatitis C achieved a sustained viral response after treatment with Peginterferon-alfa-2b ( Peg-Intron ) and Ribavirin ( Rebetol ). ...


The FDA ( Food and Drug Administration ) approved Pegasys ( Peginterferon alfa-2a ) for the treatment of chronic hepatitis B ( CHB ). Pegasys is the first and only pegylated Interferon approved fo ...


Researchers at Johns Hopkins have uncovered how a majority of the genetic changes in the hepatic-C virus, the most common cause of liver disease, allow it to evade the body’s immune system during infe ...


Patients with the most common form of hepatitis B in the United States who are treated with Pegasys ( Peginterferon alfa-2a ) are more likely to achieve a sustained response than those treated with La ...


Nearly half of 118 children with chronic Hepatitis C virus ( HCV ) treated with a combination of Interferon-alpha-2b ( Intron A ) and an optimized dose of Ribavirin ( Rebetol ) achieved sustained vira ...


A study in Japan examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower l ...


Liver transplant patients with hepatitis C virus ( HCV ) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine ( Sandimmun Neoral ) along with Int ...


Obese patients chronically infected with the hepatitis C virus ( HCV ) and treated with combination drug therapy may have better outcomes if the underlying abnormalities caused by excessive fat tissue ...


Individuals with chronic hepatitis C being treated with Interferon ( IFN ) are at risk of developing retinopathy as early as two weeks into treatment according to the results of a study published in t ...


Final results from the REPEAT study have demonstrated that treatment with once-weekly Pegasys ( Peginterferon alfa-2a ) and daily Copegus ( Ribavirin ) can achieve viral clearance in a number of patie ...


Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers.The study found ...


For patients with the most common form of hepatitis C, the addition of a hepatitis C–specific protease inhibitor called Telaprevir to the current standard therapy can significantly improve the chances ...


Sexual impairment is common among men with chronic hepatitis C undergoing antiviral therapy, according to a new study published in Gastroenterology.This is the first time a study evaluating the combin ...


Researchers at Cedars-Sinai Medical Center and 50 other Centers found that weight-based dosing of Taribavirin ( Viramidine ) reduces rates of anemia while increasing sustained virologic response ( SVR ...